Ref (type)	Population	Outcome, Interventions	Results and statistical analysis	Effect size	Favours
Adverse effects
RCT	247 people	Mean change from baseline in Simpson-Angus Scale 0 with ziprasidone (mean modal dose 149 mg/day) 0 with aripiprazole (mean modal dose 20.9 mg/day)	P = 0.99		Not significant
RCT	247 people	Mean change from baseline in Barnes Akathisia Scale +0.1 with ziprasidone (mean modal dose 149 mg/day) –0.1 with aripiprazole (mean modal dose 20.9 mg/day)	P = 0.05		Not significant
RCT	247 people	Mean change from baseline in Abnormal Involuntary Movement Scale 0 with ziprasidone (mean modal dose 149 mg/day) –0.4 with aripiprazole (mean modal dose 20.9 mg/day)	P = 0.04	Effect size not calculated	aripiprazole
RCT	247 people	Median weight gain (kg) 0.45 kg with ziprasidone (mean modal dose 149 mg/day) 0.45 kg with aripiprazole (mean modal dose 20.9 mg/day)	Significance assessment not performed
RCT	247 people	Median change from baseline in prolactin concentration (ng/mL) –2.6 ng/mL with ziprasidone (mean modal dose 149 mg/day) –9.8 ng/mL with aripiprazole (mean modal dose 20.9 mg/day)	Significance assessment not performed
RCT	247 people	Median change from baseline in QTc interval (ms) 9.0 ms with ziprasidone (mean modal dose 149 mg/day) 2.5 ms with aripiprazole (mean modal dose 20.9 mg/day)	Significance assessment not performed
RCT	247 people	Percentage of people with akathisia 6% with ziprasidone (mean modal dose 149 mg/day) 7% with aripiprazole (mean modal dose 20.9 mg/day) Absolute numbers not reported	Significance assessment not performed
RCT	247 people	Percentage of people with somnolence 26% with ziprasidone (mean modal dose 149 mg/day) 13% with aripiprazole (mean modal dose 20.9 mg/day) Absolute numbers not reported	Significance assessment not performed
RCT	247 people	Percentage of people with dyspepsia 10% with ziprasidone (mean modal dose 149 mg/day) 18% with aripiprazole (mean modal dose 20.9 mg/day) Absolute numbers not reported	Significance assessment not performed